It's also important to note that HOLX currently trades at a PEG ratio of 2.47. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Instruments was holding an average PEG ratio of 2.47 at yesterday's closing price. Hologic (HOLX) closed the latest trading day at $74.53, indicating a +0.58% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0 ...

However, a deteriorating geopolitical situation, supply chain bottlenecks leading to a tough situation related to raw material and labor costs, freight charges, as well as healthcare staffing shortages, have put the industry in a tight spot again. Meanwhile, industry players like Hologic, Inc. (HOLX) , Masimo Corporation (MASI) and Veracyte, Inc. (VCYT) have adapted well to changing consumer preferences and are still witnessing an uptrend in their stock prices. The Zacks Medical - Instruments industry is hi ...

Core Viewpoint - Stephens initiated coverage on Hologic Inc, highlighting its strong position in women's health and potential for growth in the molecular diagnostics sector post-COVID [1] Company Overview - Hologic is recognized as a leader in women's health with a portfolio of products that are considered the gold standard for care [1] - The company has demonstrated consistent revenue growth, strong free cash flow, and attractive profit margins [1] Growth Potential - Hologic emerged from the pandemic with new growth drivers, a scaled installed base, and a stronger balance sheet [1] - Near-term growth of 5%-7% is deemed achievable, while long-term growth will heavily rely on mergers and acquisitions (M&A) [6] M&A Strategy - Management has prioritized M&A for capital allocation, indicating a willingness to pursue both smaller tuck-in deals and larger acquisitions over $1 billion if suitable opportunities arise [3][7] - The focus on M&A is expected to present significant opportunities for multiple expansion and drive stock performance over the next year [6][7] Market Reaction - Hologic's shares have seen a 2.05% increase, reaching $73.76 [8]

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. Investors interested in stocks from the Medical - Instruments sector have probably already heard of Hologic (HOLX) and Edwards Lifesciences (EW) . But which of these two sto ...

The most recent trading session ended with Hologic (HOLX) standing at $71.65, reflecting a -1.15% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily gain of 0.09%. At the same time, the Dow lost 0.1%, and the tech-heavy Nasdaq gained 0.16%. The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company is forecasted to report an EPS of $1.02, showcasing a 9.68% upward movement from the corr ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sellside) analysts often affect a stock's price, do they really matter? Hologic currently has an average brokerage recommendation (ABR) of 2.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 14 brokerage firms. An ABR of 2. ...

Core Insights - Hologic (HOLX) has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision compared to Edwards Lifesciences (EW), which has a Zacks Rank of 3 (Hold) [1] - Value investors may find HOLX to be a better investment option due to its superior performance in both Zacks Rank and Style Scores models [3] Valuation Metrics - HOLX has a forward P/E ratio of 18.26, significantly lower than EW's forward P/E of 31.82, suggesting that HOLX may be undervalued [2] - The PEG ratio for HOLX is 2.48, while EW's PEG ratio is higher at 3.22, indicating that HOLX has a more favorable earnings growth expectation relative to its price [2] - HOLX's P/B ratio stands at 3.59, compared to EW's P/B of 7.39, further supporting the notion that HOLX is undervalued relative to its book value [9] Value Assessment - The Value category of the Style Scores system evaluates companies based on key metrics such as P/E ratio, P/S ratio, earnings yield, and cash flow per share to determine fair value [5] - HOLX has a Value grade of B, while EW has a Value grade of D, highlighting HOLX's stronger position in terms of value metrics [6]

Market Overview - Investors' optimism has driven the market to record highs following the U.S. Federal Reserve's policy update, which confirmed rate cut expectations in 2024, but a bearish outlook is maintained by some strategists warning of a potential downturn [1][11] - Geopolitical turmoil, including the Israel-Hamas conflict, the Russia-Ukraine war, and tensions between China and Taiwan, has led to rising raw material costs and supply-chain disruptions, causing margin pressure for many companies [2] Company Analysis Option Care Health (OPCH) - Option Care Health has a Zacks Rank of 2 (Buy) and a Value Score of B, with a forward 12-month Price/Sales ratio of 1.02, lower than its median of 1.14 and significantly discounted compared to the S&P 500's 3.99 [6][10] - The company has shown resilience post-cybersecurity incident, maintaining a patient satisfaction rate of 93% and a Net Promoter Score of 76.2, while focusing on operational excellence and growth [5][14] - OPCH's earnings yield is 4.01%, with projected earnings growth of 15.71% for 2025 [16] Lantheus (LNTH) - Lantheus holds a Zacks Rank of 2 and a Value Score of A, with a forward 12-month Price/Sales ratio of 3.72, compared to its median of 3.42 and discounted against the S&P 500's 3.99 [18] - The company is focused on operational excellence and innovation, particularly with its PYLARIFY imaging agent for prostate cancer, which is projected to generate sales of nearly $1 billion this year [7][8] - Lantheus has an earnings yield of 8.72% and anticipates earnings growth of 14.13% for 2024 [8] Hologic (HOLX) - Hologic also has a Zacks Rank of 2 and a Value Score of B, with a forward 12-month Price/Sales ratio of 4.18, lower than its median of 4.31 and discounted compared to the S&P 500's 3.99 [10] - The company has expanded its product offerings significantly, with a 40% growth in its international business since 2019, and has over $2 billion in cash to fund initiatives and acquisitions [9][19] - Hologic's earnings yield is 5.47%, with projected earnings growth of 3.03% for fiscal 2024 [20]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Hologic (HOLX), and emphasizes the importance of validating these recommendations with other indicators like the Zacks Rank. Group 1: Brokerage Recommendations - Hologic has an average brokerage recommendation (ABR) of 2.00, indicating a Buy, based on recommendations from 14 brokerage firms, with 42.9% as Strong Buy and 14.3% as Buy [2] - Brokerage analysts tend to exhibit a strong positive bias in their ratings, often issuing five "Strong Buy" recommendations for every "Strong Sell" [5] - The ABR is calculated solely from brokerage recommendations and is typically displayed in decimals, while the Zacks Rank is a quantitative model based on earnings estimate revisions [8] Group 2: Zacks Rank - The Zacks Rank for Hologic is 2 (Buy), reflecting a 1.4% increase in the Zacks Consensus Estimate for the current year to $4.08, indicating positive earnings prospects [12][13] - The Zacks Rank is timely and reflects the latest earnings estimate revisions, which are strongly correlated with near-term stock price movements [10][11] - The Zacks Rank maintains a balance among the five ranks it assigns, unlike the ABR, which may not always be up-to-date [11]

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Hologic (HOLX) .Hologic currently has an average brokerage recomm ...